The Swiss drugmaker cited solid sales growth and productivity gains, even as recent clinical-trial setbacks hit its bottom ...

Novartis AG improved its full-year profit outlook on Tuesday after stronger demand for newer medicines helped offset generic ...

By Patricia Weiss, Bhanvi Satija and Marleen Kaesebier ZURICH/LONDON, Oct 27 (Reuters) - Novartis recorded about $2.2 billion ...

Two late-stage clinical failures of high-value projects have not changed CEO Vas Narasimhan’s projection for Novartis over ...

Investor Relations Executive Director - Isabella Singh ...

Novartis lifted the veil on its phase 3 wins in relapsing multiple sclerosis (RMS) announced in early September.  | In new ...

By Patricia Weiss, Bhanvi Satija and Marleen Kaesebier ZURICH/LONDON, Oct 27 (Reuters) - Novartis booked a $1.9 billion ...

Novartis (NYSE:NVS) reported third-quarter sales growth and margin expansion, supported by demand for priority medicines and ...

A multiple sclerosis treatment from Novartis cut by a third the rates of relapses that people with the condition have ...

Novartis CEO, Vas Narasimhan, discusses how AI is beginning to impact the company’s operations. Narasimhan was speaking to ...

Swiss drugmaker Novartis is trimming costs faster than it anticipated, its CFO says. It's using artificial intelligence to ...

Q3 net sales grew +4% (cc ¹, +4% USD), with core operating income ¹ +10% (cc, +11% USD) Sales growth driven by priorit ...